21
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18649 |
(±)15-HETE
|
Others | Others |
(±)15-HETE is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | |||
T37399 |
15(S)-HETE methyl ester
|
Others | Others |
15(S)-HETE methyl ester is a synthetic derivative of 15(S)-HETE , a major arachidonic acid metabolite from the 15-lipoxygenase pathway. Methyl esters of lipids are commonly used in formulations of nutritional supplements. | |||
T83968 |
20-HETE Intermediate 15
Methyl (5Z,8Z,11Z,14Z)-20-(acetyloxy)-5,8,11,14-eicosatetraenoate |
||
20-HETE Intermediate 15 是20-羟基二十碳四烯酸的中间体。 | |||
T37485 |
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PC
|
Others | Others |
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO). | |||
T37284 |
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE
|
Others | Others |
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HETE at the sn-2 position. It is formed in human peripheral monocytes activated by the calcium ionophore A23187 by direct oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE by 15-LO. Phosphoethanolamine (PE) HETEs (PE-HETEs), including 1-stearoyl-2-15(S)-HETE-sn-glycero-3-PE, are the main source of esterified HETE in ionophore-activated monocytes. | |||
T84605 |
15(R)-HETE
15(R)-Hydroxyeicosatetraenoic Acid |
Others | Others |
15(R)-HETE, a monohydroxy fatty acid, is synthesized from arachidonic acid via aspirin-acetylated COX-2, leading to the formation of specialized pro-resolving mediators 15(R)-lipoxin A4 and B4 through a transcellular mechanism involving 5-lipoxygenase (5-LO). Additionally, this compound is produced by the cytochrome P450 (CYP) isoform CYP2C9 and can be generated from arachidonic acid by COX-1 in human mast cells, where it accumulates due to its resistance to conversion into 15-KETE by 15-hydroxy... | |||
T26956 |
CAY10397
|
Others | Others |
CAY10397, a selective inhibitor of 15-hydroxy PGDH, significantly suppresses endogenous 11-oxo-ETE production with a corresponding increase in 11(R)-HETE. | |||
T35945 |
15-OxoETE
|
Others | Others |
15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. Whether this is a major pathway of 15-HETE metabolism is yet to be clearly established. | |||
T37650 |
5(S),15(S)-DiHETE
|
Others | Others |
5(S),15(S)-DiHETE is synthesized by 15-LO from 5(S)-HETE. It potentiates the degranulation of human PMNL in response to PAF, but not fMLP, calcium ionophore A23187, or LTB4. 5(S),15(S)-DiHETE is chemotactic for eosinophils with an ED50 value of 0.3 μM. | |||
T37975 |
13(S)-HODE-biotin
|
Others | Others |
13(S)-HODE is the lipoxygenase metabolite of linoleic acid. 13(S)-HODE modulates the platelet-activating factor, leukotriene B4, and formyl-Met-Leu-Phe-induced calcium influx in human polymorphonuclear leukocytes. The mechanism by which 13(S)-HODE elicits its inhibitory effect is still unclear. The use of biotinylated 15(S)-HETE as a probe for detecting binding proteins and/or receptors that specifically bind 15(S)-HETE provides a basis for similar use of 13(S)-HODE-biotin. | |||
T84564 |
15-OxoEDE
15-KEDE |
Others | Others |
15-OxoEDE, generated through the oxidation of 15-HEDE, effectively inhibits 5-LO in RBL-1 cells with an IC50 of 55 µM, approximately half as potent as 15(S)-HEDE. Additionally, another related oxo-eicosanoid, 5-oxoETE, is produced from 5(S)-HETE via a specific dehydrogenase, exhibiting significant inflammatory activity. | |||
T37156 |
8(S),15(S)-DiHETE
|
Others | Others |
8(S),15(S)-DiHETE is formed when 15(S)-HETE is subjected to further oxidation by 15-LO. It causes eosinophil chemotaxis with an ED50 value of 1.5 μM but is not chemotactic for neutrophils. 8(S),15(S)-DiHETE antagonizes the hyperalgesic activity of 8(R),15(S)-DiHETE and LTB4 in the rat hind paw pain model. | |||
T36562 |
(5Z,11Z,15R)-15-Hydroxyeicosa-5,11-dien-13-ynoic Acid
|
Others | Others |
(5Z,11Z,15R)-15-Hydroxyeicosa-5,11-dien-13-ynoic acid is a stable isomer of 15(S)-HETE , a major arachidonic acid metabolite from the 15-lipoxygenase pathway. (5Z,11Z,15R)-15-Hydroxyeicosa-5,11-dien-13-ynoic acid elicits concentration-dependent contraction of isolated pulmonary arteries from rabbits and inhibits the proliferation and migration of hormone-independent prostate carcinoma PC-3 cells. | |||
T35943 |
15(S)-HpETE
|
Others | Others |
15(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of 15-lipoxygenase (15-LO) on arachidonic acid. It is either metabolized to 14,15-leukotriene A4 [1] or reduced to 15(S)-HETE by peroxidases.[2] [1] 15(S)-HpETE mediates a number of biological functions including the induction of c-fos and c-jun, and activation of AP-1. [3] 15(S)-HpETE inhibits prostacyclin synthesis in porcine aortic microsomes and bovine endothelial cells, and can cause the suicide inac... | |||
T37460 |
Lipoxin B4
Lipoxin B4 |
Others | Others |
Lipoxin B4 (LXB4) is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15(S)-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T36462 |
CAY10770
CAY10770 |
Others | Others |
CAY10770 is an inhibitor of the cytochrome P450 (CYP) isoform CYP4Z1 (IC50= 5.9 μM).1It is selective for CYP4Z1 over CYP4A11, CYP4F2, CYP4F3a, CYP4F3b (IC50s = 187-282 μM) but does inhibit CYP4F8 and CYP4F12 (IC50s = 167 and 91 μM, respectively). CAY10770 (3 μM) inhibits the production of 14(15)-EET, 19-HETE, and 14(15)-DiHET by 83, 86, and 80%, respectively, in T47D breast cancer cells expressing CYP4Z1. 1.Kowalski, J.P., McDonald, M.G., Pelletier, R.D., et al.Design and characterization of the... | |||
T38308 |
Lipoxin B4 methyl ester
|
Others | Others |
Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4 . LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM. | |||
T36052 |
Lipoxin A4 methyl ester
LXA4 methyl ester |
Others | Others |
Lipoxin A4 methyl ester (LXA4 methyl ester) is a more lipid soluble, prodrug formulation of the transcellular metabolite LXA4. LXA4 is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of 15-HETE or 15-HpETE with human leukocytes.[1] LXA4 is equipotent to leukotriene B4 (LTB4) in inducing superoxide generation in human neutrophils at 0.1 μM.[2] LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural... | |||
T37265 |
15(R)-Lipoxin A4
15(R)-Lipoxin A4,AT-Lipoxin A4 |
Others | Others |
Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment and function. 15(R)-Lipoxin A4 (15(R)-LXA4) is derived from the aspirin-triggered formation of 15(R)-HETE from arachidonic acid. [1] [2] 15(R)-LXA4 inhibits LTB4-induced chemotaxis, adherence, and transmigration of neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.[2] [3] The anti-inflammatory effects of aspirin may... | |||
T35918 |
N-Arachidonoyl Taurine
|
Others | Others |
N-Arachidonoyl taurine is an arachidonoyl amino acid. It is oxygenated by 12(S)- and 15(S)-lipoxygenase and is converted to 12-HETE-taurine (12-HETE-T) in murine resident peritoneal macrophages. N-Arachidonoyl taurine is an activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 (EC50s = 28 and 21 μM, respectively). It increases calcium flux in HIT-T15 pancreatic β-cells and INS-1 rat islet cells when used at a concentration of 10 μM and increases insulin secretio... | |||
T37305 |
6(S)-Lipoxin A4
6(S)-Lipoxin A4 |
Others | Others |
The lipoxins are trihydroxy fatty acids containing a 7,9,11,13-conjugated tetraene. Lipoxin A4 (LXA4) was first described as a metabolite of 15-HpETE and/or 15-HETE when added in vitro to isolated human leukocytes. The material obtained in this manner consists of at least four distinct isomers: 5(S), 6(S); 5(S), 6(R); and the 11-trans and 11-cis isomers of each of these. 6(S)-LXA4 is one of the original four metabolites first identified by Serhan, Nicolaou, and Samuelsson. It was considered to b... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36051 |
Lipoxin A4
脂氧素 A4,LXA4 |
Others | Others |
Lipoxin A4 (LXA4) is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of (±)15-HETE or 15-HpETE with human leukocytes.[1] LXA4 is equipotent to leukotriene B4 in inducing superoxide generation in human neutrophils at 0.1 μM.2 LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural killer cell inhibition, and monocyte migration and adhesion.[2],[3],[4] Analytical and biological comparisons of synth... |